4883.T) reported the exercise of its 17th series warrants (with adjustment clause)">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from Modalis Therapeutics Corporation was processed by Pulse News Wire on March 17, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Modalis Therapeutics: Reports Exercise of Warrants Issued to EVO Fund

TOKYO, Mar 17 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) reported the exercise of its 17th series warrants (with adjustment clause) issued to EVO Fund during the period from March 2

View all 4883.T disclosures →

Share this disclosure: Share on X Share on LinkedIn